Lates News

Novartis CEO Vas Narasimhan said in an interview on Saturday that the company is studying a plan to propose a price reduction to President Trump before the end of this month. Narasimhan said, "We are working with the government to find practical solutions so that the American people can buy drugs at lower prices." He added that the company is also working to eliminate the price gap between drugs in the United States and other industrialized countries. Narasimhan said that Novartis has not adjusted its expectations due to Trump's requests and still expects revenue to increase by 5% from mid-2024 to mid-2029, with profit growth outpacing revenue growth. Narasimhan also said that Novartis is prepared for the 15% tariff that the US imposes on drugs from the European Union, stating, "We have significantly increased our inventory in the United States, so this inventory should last until mid-2026."